NuVasive Stock Price, News & Analysis (NASDAQ:NUVA)

$57.29 0.60 (1.06 %)
(As of 11/17/2017 02:10 PM ET)
Previous Close$57.29
Today's Range$57.92 - $56.36
52-Week Range$49.25 - $81.68
Volume674,778 shs
Average Volume863,166 shs
Market Capitalization$2.89 billion
P/E Ratio29.78
Dividend YieldN/A
Beta0.78

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.


Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Sector: Medical Equipment, Supplies & Distribution - NEC
  • Symbol: NASDAQ:NUVA
  • CUSIP: 67070410
  • Web: www.nuvasive.com
Debt:
  • Debt-to-Equity Ratio: 0.76%
  • Current Ratio: 2.85%
  • Quick Ratio: 1.51%
Price-To-Earnings:
  • Trailing P/E Ratio: 29.78
  • Forward P/E Ratio: 29.99
  • P/E Growth: 2
Sales & Book Value:
  • Annual Sales: $962.07 million
  • Price / Sales: 3.04
  • Cash Flow: $4.28 per share
  • Price / Cash: 13.38
  • Book Value: $14.91 per share
  • Price / Book: 3.84
Profitability:
  • Trailing EPS: $1.19
  • Net Income: $37.14 million
  • Net Margins: 6.36%
  • Return on Equity: 13.65%
  • Return on Assets: 6.17%
Misc:
  • Employees: 2,200
  • Outstanding Shares: 50,970,000
 

Frequently Asked Questions for NuVasive (NASDAQ:NUVA)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive announced that its Board of Directors has approved a stock buyback program on Wednesday, October 25th 2017, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Tuesday, October, 24th. The medical device company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.04. The medical device company earned $247.40 million during the quarter, compared to the consensus estimate of $255.70 million. NuVasive had a net margin of 6.36% and a return on equity of 13.65%. NuVasive's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.40 earnings per share. View NuVasive's Earnings History.

When will NuVasive make its next earnings announcement?

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY17 earnings guidance on Tuesday, October, 24th. The company provided earnings per share guidance of $1.91 for the period, compared to the Thomson Reuters consensus estimate of $1.99. The company issued revenue guidance of $1.030 billion, compared to the consensus revenue estimate of $1.09 billion.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2017?

16 Wall Street analysts have issued 1-year price targets for NuVasive's shares. Their forecasts range from $60.00 to $90.00. On average, they anticipate NuVasive's share price to reach $71.64 in the next twelve months. View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. Needham & Company LLC analysts commented, "NUVA’s 3Q17 revenue missed, although EPS beat consensus. More importantly, management lowered its 2017 guidance. Reported revenue growth slowed to 3% in 3Q17 from 5% in 2Q17 as the US spine market slowed and NUVA’s biologics continued its decline. Revenue growth was ~6% adjusting for the unexpected impact of the hurricanes (~$5M) and the expected impact of one less selling day (~$3M). NUVA’s operating margin beat consensus and increased 150 bps Y/Y. Management’s updated 2017 guidance implies flat Y/Y revenue in 4Q17. Even if we assume that guidance for no growth in 4Q17 is conservative, it makes NUVA’s mid- single digit revenue growth target for 2018 look challenging." (10/25/2017)
  • 2. According to Zacks Investment Research, "NuVasive’s second-quarter 2017 performance was mixed with the bottom line beating the estimates and sales missing the mark. However, year-over-year, revenue growth was solid, led by robust performance in the international market on above-market growth across all geographies. Notably, over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. We are optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, over the last three months, NuVasive has been trading below the broader industry. Further, currency headwind, pricing and reimbursement issues along with a competitive landscape are major downsides. Also, the company’s low-margin Biotronic business impacted the second quarter’s performance." (7/31/2017)
  • 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
  • 4. UBS AG analysts commented, "The company's long-term operating margin goal of 25% was a key topic of discussion last week when we hosted NUVA for investor meetings. Management laid out a clear pathway to 25% operating margins (from 16.1% currently), which included: 1) 400 bps from in-source manufacturing; 2) 400 bps from asset efficiencies; 3) 400 bps from OUS scalability; and 4) 200 bps from sales force efficiencies, offset by 500 bps of R&D investment and pricing headwinds. We reiterate our Buy rating on NUVA and $82 price target and expect consistent execution and margin improvements to drive the stock higher." (3/20/2017)

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:

  • Gregory T. Lucier, Chairman of the Board, Chief Executive Officer (Age 53)
  • Rajesh J. Asarpota, Chief Financial Officer, Executive Vice President (Age 50)
  • Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary (Age 52)
  • Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing (Age 52)
  • Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications (Age 53)
  • Matthew W. Link, Executive Vice President - Strategy, Technology and Corporate Development (Age 42)
  • Stephen Rozow, - Global Process Transformation (Age 48)
  • Vickie L. Capps, Independent Director (Age 55)
  • Peter C. Farrell Ph.D., Independent Director (Age 75)
  • Robert F. Friel, Independent Director (Age 61)

Who owns NuVasive stock?

NuVasive's stock is owned by a number of of institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (3.06%), Fisher Asset Management LLC (2.57%), Eagle Asset Management Inc. (2.22%), American Century Companies Inc. (1.94%), Dimensional Fund Advisors LP (1.87%) and Rothschild Asset Management Inc. (1.04%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Peter Michael Leddy and Quentin S Blackford. View Institutional Ownership Trends for NuVasive.

Who sold NuVasive stock? Who is selling NuVasive stock?

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Victory Capital Management Inc., Eagle Asset Management Inc., Neuberger Berman Group LLC, Sectoral Asset Management Inc, Prudential Financial Inc., Highbridge Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold NuVasive company stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link. View Insider Buying and Selling for NuVasive.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Sector Gamma AS, American Capital Management Inc., Orbimed Advisors LLC, Elk Creek Partners LLC, C WorldWide Group Holding A S, Empire Life Investments Inc. and State of Wisconsin Investment Board. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NuVasive stock can currently be purchased for approximately $57.29.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.89 billion and generates $962.07 million in revenue each year. The medical device company earns $37.14 million in net income (profit) each year or $1.19 on an earnings per share basis. NuVasive employs 2,200 workers across the globe.

How can I contact NuVasive?

NuVasive's mailing address is 7475 Lusk Blvd, SAN DIEGO, CA 92121-5707, United States. The medical device company can be reached via phone at +1-858-9091800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NASDAQ NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  519 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  931
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for NuVasive (NASDAQ:NUVA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 13 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $71.64 (25.05% upside)

Consensus Price Target History for NuVasive (NASDAQ:NUVA)

Price Target History for NuVasive (NASDAQ:NUVA)

Analysts' Ratings History for NuVasive (NASDAQ:NUVA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$75.00 -> $70.00N/AView Rating Details
10/25/2017BMO Capital MarketsLower Price TargetOutperform$85.00 -> $69.00N/AView Rating Details
10/25/2017BTIG ResearchSet Price TargetBuy$74.00N/AView Rating Details
10/25/2017Needham & Company LLCReiterated RatingSellN/AView Rating Details
10/25/2017Wells Fargo & CompanyReiterated RatingOutperform$81.00 -> $65.00N/AView Rating Details
10/25/2017J P Morgan Chase & CoSet Price TargetBuy$78.00N/AView Rating Details
10/25/2017Canaccord GenuityReiterated RatingBuy$75.00 -> $70.00N/AView Rating Details
10/19/2017Barclays PLCLower Price TargetOverweight$80.00 -> $65.00N/AView Rating Details
10/12/2017Robert W. BairdSet Price TargetHold$72.00 -> $60.00N/AView Rating Details
10/12/2017Cowen and CompanySet Price TargetBuy$72.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$74.00 -> $69.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$81.00 -> $70.00N/AView Rating Details
10/3/2017Jefferies Group LLCReiterated RatingBuy$79.00LowView Rating Details
9/28/2017Piper Jaffray CompaniesReiterated RatingBuy$90.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
12/11/2015Bank of America CorporationUpgradeUnderperform -> Neutral$56.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for NuVasive (NASDAQ:NUVA)

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

Earnings History by Quarter for NuVasive (NASDAQ NUVA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018$0.67N/AView Earnings Details
10/24/2017Q3 2017$0.48$0.52$255.70 million$247.40 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.44$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NuVasive (NASDAQ:NUVA)
2017 EPS Consensus Estimate: $1.90
2018 EPS Consensus Estimate: $2.26
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.37$0.39$0.38
Q2 20173$0.44$0.48$0.46
Q3 20173$0.44$0.55$0.50
Q4 20173$0.55$0.56$0.56
Q1 20183$0.41$0.51$0.45
Q2 20183$0.55$0.59$0.57
Q3 20183$0.57$0.58$0.58
Q4 20183$0.63$0.71$0.66
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NuVasive (NASDAQ:NUVA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NuVasive (NASDAQ NUVA)

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)

Insider Trades by Quarter for NuVasive (NASDAQ NUVA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.38View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.69View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.12View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.00View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.23View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.00View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.08View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.00View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.84View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.24View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.00View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.00View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.00View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.72View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.00View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.00View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.00View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.00View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.93View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.00View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.50View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.59View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.00View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.00View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.95View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.68View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NuVasive (NASDAQ:NUVA)

Latest Headlines for NuVasive (NASDAQ NUVA)

Source:
DateHeadline
NuVasive To Participate In The 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)NuVasive To Participate In The 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 18 at 9:04 AM
5 Supernova Stocks That Have Flown Under the Radar: NuVasive5 Supernova Stocks That Have Flown Under the Radar: NuVasive
www.fool.com - November 16 at 12:46 AM
NuVasive, Inc. (NUVA) Given New $70.00 Price Target at Royal Bank Of CanadaNuVasive, Inc. (NUVA) Given New $70.00 Price Target at Royal Bank Of Canada
www.americanbankingnews.com - November 12 at 1:10 PM
NuVasive, Inc. (NUVA) Expected to Post Earnings of $0.56 Per ShareNuVasive, Inc. (NUVA) Expected to Post Earnings of $0.56 Per Share
www.americanbankingnews.com - November 12 at 1:08 AM
NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : November 6, 2017NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : November 6, 2017
finance.yahoo.com - November 7 at 7:55 AM
ETFs with exposure to NuVasive, Inc. : November 6, 2017ETFs with exposure to NuVasive, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 7:55 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA) - Business Wire (press release)
www.businesswire.com - November 1 at 7:04 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA)Glancy Prongay & Murray LLP Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA)
finance.yahoo.com - November 1 at 7:04 AM
NuVasive, Inc. (NUVA) to Post FY2021 Earnings of $3.30 Per Share, Gabelli ForecastsNuVasive, Inc. (NUVA) to Post FY2021 Earnings of $3.30 Per Share, Gabelli Forecasts
www.americanbankingnews.com - October 30 at 12:10 PM
NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : October 26, 2017NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : October 26, 2017
finance.yahoo.com - October 28 at 9:55 AM
NuVasive, Inc. :NUVA-US: Earnings Analysis: Q3, 2017 By the Numbers : October 26, 2017NuVasive, Inc. :NUVA-US: Earnings Analysis: Q3, 2017 By the Numbers : October 26, 2017
finance.yahoo.com - October 28 at 9:55 AM
ETFs with exposure to NuVasive, Inc. : October 27, 2017ETFs with exposure to NuVasive, Inc. : October 27, 2017
finance.yahoo.com - October 28 at 9:55 AM
FY2020 EPS Estimates for NuVasive, Inc. (NUVA) Cut by Jefferies GroupFY2020 EPS Estimates for NuVasive, Inc. (NUVA) Cut by Jefferies Group
www.americanbankingnews.com - October 27 at 7:48 PM
NuVasive, Inc. Expected to Earn Q1 2018 Earnings of $0.41 Per Share (NUVA)NuVasive, Inc. Expected to Earn Q1 2018 Earnings of $0.41 Per Share (NUVA)
www.americanbankingnews.com - October 27 at 2:38 PM
NuVasive, Inc. Expected to Post Q4 2017 Earnings of $0.56 Per Share (NUVA)NuVasive, Inc. Expected to Post Q4 2017 Earnings of $0.56 Per Share (NUVA)
www.americanbankingnews.com - October 27 at 12:12 PM
NuVasive Unveils Latest Innovation At NASS 2017 - PR Newswire (press release)NuVasive Unveils Latest Innovation At NASS 2017 - PR Newswire (press release)
www.prnewswire.com - October 27 at 8:46 AM
Heres Why NuVasive, Inc. Popped Today - Motley FoolHere's Why NuVasive, Inc. Popped Today - Motley Fool
www.fool.com - October 27 at 8:45 AM
Research Analysts Offer Predictions for NuVasive, Inc.s FY2017 Earnings (NUVA)Research Analysts Offer Predictions for NuVasive, Inc.'s FY2017 Earnings (NUVA)
www.americanbankingnews.com - October 27 at 7:42 AM
Jefferies Group Weighs in on NuVasive, Inc.s FY2017 Earnings (NUVA)Jefferies Group Weighs in on NuVasive, Inc.'s FY2017 Earnings (NUVA)
www.americanbankingnews.com - October 26 at 9:16 AM
NuVasive, Inc. (NUVA) to Post FY2017 Earnings of $1.91 Per Share, Leerink Swann ForecastsNuVasive, Inc. (NUVA) to Post FY2017 Earnings of $1.91 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - October 26 at 9:16 AM
William Blair Weighs in on NuVasive, Inc.s FY2017 Earnings (NUVA)William Blair Weighs in on NuVasive, Inc.'s FY2017 Earnings (NUVA)
www.americanbankingnews.com - October 26 at 9:16 AM
NuVasive, Inc. (NUVA) Given Consensus Recommendation of "Buy" by BrokeragesNuVasive, Inc. (NUVA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 9:34 PM
Financial Review: NuVasive (NUVA) versus The CompetitionFinancial Review: NuVasive (NUVA) versus The Competition
www.americanbankingnews.com - October 25 at 9:10 PM
Heres Why NuVasive, Inc. Popped TodayHere's Why NuVasive, Inc. Popped Today
www.fool.com - October 25 at 4:59 PM
Why Akamai Technologies, NuVasive, and MacroGenics Jumped TodayWhy Akamai Technologies, NuVasive, and MacroGenics Jumped Today
www.fool.com - October 25 at 4:58 PM
NuVasive, Inc. (NUVA) Price Target Lowered to $69.00 at BMO Capital MarketsNuVasive, Inc. (NUVA) Price Target Lowered to $69.00 at BMO Capital Markets
www.americanbankingnews.com - October 25 at 4:43 PM
NuVasive (NUVA) Approves Stock Buyback ProgramNuVasive (NUVA) Approves Stock Buyback Program
www.americanbankingnews.com - October 25 at 11:13 AM
NuVasive Updates 2017 Guidance; Announces $100 Mln Share Repurchase ProgramNuVasive Updates 2017 Guidance; Announces $100 Mln Share Repurchase Program
www.rttnews.com - October 25 at 8:24 AM
NuVasive, Inc. Reports 27% Advance In Q3 Bottom LineNuVasive, Inc. Reports 27% Advance In Q3 Bottom Line
www.nasdaq.com - October 25 at 8:24 AM
NuVasives (NUVA) CEO Greg Lucier on Q3 2017 Results - Earnings Call TranscriptNuVasive's (NUVA) CEO Greg Lucier on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 25 at 8:24 AM
BRIEF-NuVasive Inc reports Q3 GAAP earnings per share $0.64BRIEF-NuVasive Inc reports Q3 GAAP earnings per share $0.64
www.reuters.com - October 25 at 8:24 AM
NuVasive, Inc. to Host Earnings CallNuVasive, Inc. to Host Earnings Call
finance.yahoo.com - October 25 at 8:24 AM
NuVasive Reports Third Quarter 2017 Financial ResultsNuVasive Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 25 at 8:24 AM
NuVasive Announces $100 Million Share Repurchase ProgramNuVasive Announces $100 Million Share Repurchase Program
finance.yahoo.com - October 25 at 8:23 AM
NuVasive beats 3Q profit forecastsNuVasive beats 3Q profit forecasts
finance.yahoo.com - October 25 at 8:23 AM
NuVasive's Sluggish Sales Growth Prompts BuybacksNuVasive's Sluggish Sales Growth Prompts Buybacks
finance.yahoo.com - October 25 at 8:23 AM
Edited Transcript of NUVA earnings conference call or presentation 24-Oct-17 8:30pm GMTEdited Transcript of NUVA earnings conference call or presentation 24-Oct-17 8:30pm GMT
finance.yahoo.com - October 25 at 8:23 AM
NuVasives (NUVA) "Sell" Rating Reiterated at Needham & Company LLCNuVasive's (NUVA) "Sell" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - October 25 at 7:50 AM
NuVasive, Inc. (NUVA) Receives Outperform Rating from Wells Fargo & CompanyNuVasive, Inc. (NUVA) Receives Outperform Rating from Wells Fargo & Company
www.americanbankingnews.com - October 25 at 7:50 AM
NuVasive, Inc. (NUVA) Releases Quarterly  Earnings Results, Beats Expectations By $0.04 EPSNuVasive, Inc. (NUVA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - October 24 at 9:08 PM
NuVasives Sluggish Sales Growth Prompts BuybacksNuVasive's Sluggish Sales Growth Prompts Buybacks
www.fool.com - October 24 at 7:52 PM
NuVasive, Inc. (NUVA) Issues FY17 Earnings GuidanceNuVasive, Inc. (NUVA) Issues FY17 Earnings Guidance
www.americanbankingnews.com - October 24 at 5:46 PM
NuVasive Q3 top line up 4%; non-GAAP earnings up 27%; shares down 4% after hours on revenue missNuVasive Q3 top line up 4%; non-GAAP earnings up 27%; shares down 4% after hours on revenue miss
seekingalpha.com - October 24 at 5:29 PM
NuVasive (NUVA) vs. Its Peers Head-To-Head AnalysisNuVasive (NUVA) vs. Its Peers Head-To-Head Analysis
www.americanbankingnews.com - October 24 at 12:30 PM
NuVasive Extends Its Leadership As Lateral Spine Technology Innovator With New Lateral Single-Position Surgery ProcedureNuVasive Extends Its Leadership As Lateral Spine Technology Innovator With New Lateral Single-Position Surgery Procedure
finance.yahoo.com - October 24 at 7:50 AM
NuVasive, Inc. (NUVA) Expected to Post Earnings of $0.49 Per ShareNuVasive, Inc. (NUVA) Expected to Post Earnings of $0.49 Per Share
www.americanbankingnews.com - October 23 at 12:06 AM
NuVasive's TLX Interbody System Gets Expanded FDA ApprovalNuVasive's TLX Interbody System Gets Expanded FDA Approval
finance.yahoo.com - October 20 at 6:58 AM
NuVasive, Inc. (NUVA) Rating Reiterated by Barclays PLCNuVasive, Inc. (NUVA) Rating Reiterated by Barclays PLC
www.americanbankingnews.com - October 19 at 6:58 PM
NuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio - PR Newswire (press release)NuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio - PR Newswire (press release)
www.prnewswire.com - October 19 at 7:00 AM
NuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science PortfolioNuVasive Launches New 3D-Printed Porous Titanium Implant In Expanding Advanced Materials Science Portfolio
finance.yahoo.com - October 19 at 7:00 AM

Social Media

Financials

Chart

NuVasive (NASDAQ NUVA) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.